Clinical trials: Gliosarcoma of Brain
Glioblastoma, Gliosarcoma
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Primary objective: To evaluate activity of imatinib mesylate and hydroxyurea among patients with progressive/recurrent grade II low-grade glioma (LGG) as measured by 12-month progression free survival Secondary objectives: To…
- Trial name
- NCT00615927
- Testing
- Imatinib Mesylate & Hydroxyurea
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Duke University